This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly ...
--Eli Lilly and Company today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3 b trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in ...